NTLA Intellia Therapeutics Inc.

22.33
+2.07  (+10%)
Previous Close 20.26
Open 20.5
Price To Book 4.63
Market Cap 1,147,326,096
Shares 51,380,479
Volume 4,201,316
Short Ratio
Av. Daily Volume 890,714
Stock charts supplied by TradingView

NewsSee all news

  1. Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

    CAMBRIDGE, Mass., June 02, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in

  2. Intellia Therapeutics Announces Proposed Public Offering of Common Stock

    CAMBRIDGE, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in

  3. Regeneron and Intellia Therapeutics Expand Collaboration to Develop CRISPR/Cas9-Based Treatments

    TARRYTOWN, N.Y. and CAMBRIDGE, Mass., June 1, 2020 /PRNewswire/ -- Regeneron and Intellia to co-develop potential hemophilia A and B treatments using their jointly-owned targeted transgene insertion capabilities

  4. Intellia Therapeutics Reports Progress on CRISPR/Cas9 AML Cancer Therapy Using Proprietary Cell Engineering Process at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy

    Intellia's CRISPR/Cas9 proprietary process produces multiple, highly efficient sequential edits in T cells that have superior function and minimal translocations, compared to results from standard T cell engineering

  5. Intellia Therapeutics Announces First Quarter 2020 Financial Results

    On track to submit an IND or IND-equivalent for NTLA-2001 for the treatment of transthyretin amyloidosis in mid-2020; plans to dose first patient in 2H 2020On track to submit an IND or IND-equivalent for lead TCR-T cell

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 trial to commence dosing 2H 2020.
NTLA-2001
transthyretin amyloidosis (ATTR)

Latest News

  1. Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

    CAMBRIDGE, Mass., June 02, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in

  2. Intellia Therapeutics Announces Proposed Public Offering of Common Stock

    CAMBRIDGE, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in

  3. Regeneron and Intellia Therapeutics Expand Collaboration to Develop CRISPR/Cas9-Based Treatments

    TARRYTOWN, N.Y. and CAMBRIDGE, Mass., June 1, 2020 /PRNewswire/ -- Regeneron and Intellia to co-develop potential hemophilia A and B treatments using their jointly-owned targeted transgene insertion capabilities

  4. Intellia Therapeutics Reports Progress on CRISPR/Cas9 AML Cancer Therapy Using Proprietary Cell Engineering Process at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy

    Intellia's CRISPR/Cas9 proprietary process produces multiple, highly efficient sequential edits in T cells that have superior function and minimal translocations, compared to results from standard T cell engineering

  5. Intellia Therapeutics Announces First Quarter 2020 Financial Results

    On track to submit an IND or IND-equivalent for NTLA-2001 for the treatment of transthyretin amyloidosis in mid-2020; plans to dose first patient in 2H 2020On track to submit an IND or IND-equivalent for lead TCR-T cell

  6. Intellia Therapeutics Names David Lebwohl, M.D., Chief Medical Officer

    CAMBRIDGE, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) has named David Lebwohl, M.D., as its new executive vice president and chief medical officer. Dr. Lebwohl brings decades of

  7. Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2020 Earnings and Company Updates

    CAMBRIDGE, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and

  8. Intellia Therapeutics to Present New Preclinical Data from Its CRISPR/Cas9 Programs at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy

    CAMBRIDGE, Mass., April 28, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in

  9. FDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration with Intellia Therapeutics

    CAMBRIDGE, Mass., March 31, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in

  10. Intellia Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results

    On track to submit an IND application for NTLA-2001 for the treatment of transthyretin amyloidosis in mid-2020 and to dose first patients in 2H 2020Plans to submit an IND application for NTLA-5001, a WT1-directed TCR-T

  11. Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2019 Earnings and Company Update

    CAMBRIDGE, Mass., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and

  12. Intellia Therapeutics Presents New Data From Its Engineered Cell Therapy and In Vivo Programs at Keystone Symposia's Engineering the Genome Conference

    Specific and potent tumor cell killing observed in WT1-positive acute myeloid leukemia blasts in vitro by TCR-based engineered T cells, supporting Intellia's first engineered T cell therapy development candidate,

  13. Intellia Therapeutics Highlights Recent Progress and Anticipated 2020 Milestones

    On track to submit IND application for lead candidate, NTLA-2001 for transthyretin amyloidosis, in mid-2020 and dose first patients in 2H 2020Nominated NTLA-5001 for the treatment of acute myeloid leukemia as first

  14. Intellia Therapeutics to Present at Evercore ISI 2nd Annual HealthCONx Conference

    CAMBRIDGE, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and

  15. Intellia Therapeutics Announces Third Quarter 2019 Financial Results

    On track to submit in mid-2020 an investigational new drug application for NTLA-2001 for the treatment of transthyretin amyloidosis Expects to nominate its first T cell receptor-directed engineered cell therapy

  16. Intellia Therapeutics Presents In Vivo and Ex Vivo Data at the 2019 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT)

    First reported consecutive in vivo gene knockout and insertion achieves therapeutically relevant results in an alpha-1 antitrypsin deficiency mouse modelInserted highly active WT1-TCR into the endogenous TCR locus for

  17. Intellia Therapeutics to Present at October Healthcare Investor Conferences

    CAMBRIDGE, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and

  18. Arbitration Decision Affirms Intellia Therapeutics' Interpretation of Licensing Agreement with Caribou Biosciences on the CRISPR/Cas9 Technology

    Interim Award concluded all technology in dispute was exclusively licensed to IntelliaParties must negotiate terms and payments to Intellia for Caribou's use of the chemically modified guide RNAs   CAMBRIDGE, Mass.,